Cargando…

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Anthracyclines are key components of human breast cancer chemotherapy. Here, we explored the role of Akt signaling in anthracycline resistance. The antitumor activity of doxorubicin and Akt inhibitor A-443654 alone or combined was examined in estrogen receptor (ER) positive and negative human breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yndestad, Synnøve, Austreid, Eilin, Svanberg, Ida R., Knappskog, Stian, Lønning, Per E., Eikesdal, Hans P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522318/ https://www.ncbi.nlm.nih.gov/pubmed/28476032 http://dx.doi.org/10.18632/oncotarget.17167

Ejemplares similares

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
por: Yndestad, Synnøve, et al.
Publicado: (2017)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy
por: Eikesdal, Hans P., et al.
Publicado: (2014)

Constitutional Mosaic Epimutations - a hidden cause of cancer?
por: Lønning, Per E., et al.
Publicado: (2019)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
por: Knappskog, Stian, et al.
Publicado: (2011)

Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012)

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
por: Lønning, Per Eystein, et al.
Publicado: (2018)

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
por: Huun, Johanna, et al.
Publicado: (2017)

ramr: an R/Bioconductor package for detection of rare aberrantly methylated regions
por: Nikolaienko, Oleksii, et al.
Publicado: (2021)

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data
por: Nikolaienko, Oleksii, et al.
Publicado: (2023)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012)

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
por: Lønning, Per Eystein, et al.
Publicado: (2013)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
por: Lønning, Per E., et al.
Publicado: (2022)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007)

Alterations of the retinoblastoma gene in metastatic breast cancer
por: Berge, Elisabet Ognedal, et al.
Publicado: (2011)

The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2020)

Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2021)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
por: Pedersen, Christine Aaserød, et al.
Publicado: (2022)

Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour
por: Straume, Anne Hege, et al.
Publicado: (2012)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015)

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
por: Knappskog, Stian, et al.
Publicado: (2015)

Impaired lymphatic function accelerates cancer growth
por: Steinskog, Eli Sihn Samdal, et al.
Publicado: (2016)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

APOBEC3A/B deletion polymorphism and cancer risk
por: Gansmo, Liv B, et al.
Publicado: (2018)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
por: Venizelos, Andreas, et al.
Publicado: (2022)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
por: Huun, Johanna, et al.
Publicado: (2017)

Assessment of tumor suppressor promoter methylation in healthy individuals
por: Poduval, Deepak B., et al.
Publicado: (2020)

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
por: Berge, Elisabet Ognedal, et al.
Publicado: (2010)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
por: Birkeland, Einar, et al.
Publicado: (2013)

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
por: Løes, Inger Marie, et al.
Publicado: (2014)

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate
por: Gansmo, Liv B., et al.
Publicado: (2016)

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells
por: Huun, Johanna, et al.
Publicado: (2017)

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
por: Gansmo, Liv B., et al.
Publicado: (2021)

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer
por: Helwa, Reham, et al.
Publicado: (2016)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
por: Batalini, Felipe, et al.
Publicado: (2022)

An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2020)

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aop75p7bm11rg216iu57a9qtte